Role of p53 in drug resistance in ovarian cancer

Lancet

Volumn 349, Issue 9054, 1997, Pages 744-745

  Shelling, A N ^a  

^a NATIONAL WOMEN S HOSPITAL   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; PROTEIN P53;

APOPTOSIS; CHEMOSENSITIVITY; GENE MUTATION; HUMAN; OVARY CANCER; PRIORITY JOURNAL; PROGNOSIS; SHORT SURVEY; TUMOR SUPPRESSOR GENE;

EID: 0030903281     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(05)60195-X     Document Type: Note

References (7)

1. DM Reese Anticancer drugs Nature 378 1995 532
2. GB Kristensen C Trope Epithelial ovarian cancer Lancet 349 1997 113 117
3. AN Shelling IE Cooke TS Ganesan The genetic analysis of ovarian cancer Br J Cancer 72 1995 521 527
4. JJO Herod AG Eliopoulos J Warwick G Niedobitek LS Young DJ Kerr The prognostic significance of bcl-2 and p53 expression in ovarian carcinoma Cancer Res 56 1996 2178 2184
5. F Buttita A Marchetti A Gadducci p53 alterations are predictive of chemoresistance and aggressiveness in ovarian carcinomas: a molecular and immunohistochemical study Br J Cancer 75 1997 230 235
6. SC Righetti GD Torre S Pilotti A comparative study of p53 gene mutations, protein accumulation, and response to cisplatinbased chemotherapy in advanced ovarian carcinoma Cancer Res 56 1996 689 693
7. AF Wahl KL Donaldson C Fairchild Loss of normal p53 function confers sensitization to taxol by increasing G2/M arrest and apoptosis Nat Med 2 1996 72 79